Evidence map›Paper›PMID 36671850›Full record

ArticleBiosensors2022

Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR.

Kateryna Tkachenko, Isabel Esteban-Díez, José M González-Sáiz, Patricia Pérez-Matute, Consuelo Pizarro

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kateryna TkachenkoDepartment of Chemistry, University of La Rioja, 26006 Logroño, Spain.
Isabel Esteban-DíezDepartment of Chemistry, University of La Rioja, 26006 Logroño, Spain.
José M González-SáizDepartment of Chemistry, University of La Rioja, 26006 Logroño, Spain.
Patricia Pérez-MatuteInfectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0003-2232-7971
Consuelo PizarroDepartment of Chemistry, University of La Rioja, 26006 Logroño, Spain.ORCID 0000-0001-6450-8741
Universidad de La Rioja · ESCenter for Biomedical Research of La Rioja · ES

Funding

European Union's H2020 research grant 801586Ministry of Science and Innovation CTQ2011-26603
6 · The paper itself

Abstract

Metabolic syndrome is a complex of interrelated risk factors for cardiovascular disease and diabetes. Thus, new point-of-care diagnostic tools are essential for unambiguously distinguishing MetS patients, providing results in rapid time. Herein, we evaluated the potential of Fourier transform infrared spectroscopy combined with chemometric tools to detect spectra markers indicative of metabolic syndrome. Around 105 plasma samples were collected and divided into two groups according to the presence of at least three of the five clinical parameters used for MetS diagnosis. A dual classification approach was studied based on selecting the most important spectral variable and classification methods, linear discriminant analysis (LDA) and SIMCA class modelling, respectively. The same classification methods were applied to measured clinical parameters at our disposal. Thus, the classification's performance on reduced spectra fingerprints and measured clinical parameters were compared. Both approaches achieved excellent discrimination results among groups, providing almost 100% accuracy. Nevertheless, SIMCA class modelling showed higher classification performance between MetS and no MetS for IR-reduced variables compared to clinical variables. We finally discuss the potential of this method to be used as a supportive diagnostic or screening tool in clinical routines.

Indexed as

Metabolic SyndromeDiscriminant AnalysisHumansPrincipal Component AnalysisSpectroscopy, Fourier Transform Infraredchemometricsclassification strategyhealth and wellbeing monitoringinfrared spectroscopymetabolic signaturesmetabolic syndromepoint of care

Identifiers

PMID36671850
PMCPMC9855898
OpenAlexW4312117151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.